Brunet P, Lorec A M, Leonetti F, Roubicek C, Jaber K, Roux F, Berland Y
Service de Néphrologie, Hôpital Sainte-Marguerite, Marseille, France.
Nephrol Dial Transplant. 1994;9(6):650-4. doi: 10.1093/ndt/9.6.650.
Predialysis plasma endothelin (ET) values were followed during the first 8 weeks of rHuEpo treatment in 12 patients on routine haemodialysis. Mean plasma ET was significantly increased in uraemic patients before rHuEpo (27.9 +/- 11.4 pmol/l), as compared to 40 healthy controls (16.5 +/- 5.7 pmol/l) (P < 0.0001). Under rHuEpo treatment, predialysis values remained unchanged although diastolic blood pressure increased after 2 and 6 weeks. We found no correlation between ET and haemoglobin or blood pressure before or under rHuEpo treatment. These results confirmed the high levels of plasma ET in haemodialysis patients, but no increase was observed during rHuEpo treatment.
在12例接受常规血液透析的患者中，观察了重组人促红细胞生成素（rHuEpo）治疗前8周期间的透析前血浆内皮素（ET）值。与40名健康对照者（16.5±5.7 pmol/L）相比，尿毒症患者在接受rHuEpo治疗前的平均血浆ET显著升高（27.9±11.4 pmol/L）（P<0.0001）。在rHuEpo治疗期间，透析前值保持不变，尽管舒张压在2周和6周后升高。我们发现在rHuEpo治疗前或治疗期间，ET与血红蛋白或血压之间无相关性。这些结果证实了血液透析患者血浆ET水平较高，但在rHuEpo治疗期间未观察到升高。
